Patents Granted on Bacterial Genetic Modification Technology (Xer-cise™)
RecipharmCobra Biologics today announces that the European patents on its ‘Xer-cise’ genetic engineering technology have been granted.
Xer-cise enables bacteria to be genetically modified without leaving antibiotic resistance genes on their chromosomes. Xer-cise therefore overcomes the problems caused by the biosafety risk of potentially spreading antibiotic resistance to pathogens, the limited number of available antibiotic resistance genes and the competing use of these genes on plasmids. Xer-cise utilises Xer recombinases, which are naturally present in virtually every